Nurix Therapeutics (NRIX) Common Equity (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Common Equity data on file, last reported at $480.9 million in Q1 2026.

• Common Equity for Q1 2026 came in at $480.9 million, changed 0.0% year-over-year; the trailing twelve-month figure through Feb 2026 was $480.9 million (changed 0.0% YoY), and the FY2025 annual result was $538.7 million, up 2.23% from the prior year.
• Common Equity retreated to $480.9 million in Q1 2026 per NRIX's latest filing, from $538.7 million in the prior quarter.
• Over five years, Common Equity peaked at $538.7 million in Q4 2025 and troughed at $168.7 million in Q1 2024.
• A 5-year average of $350.1 million and a median of $342.5 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 38.42% in 2024, then soared 184.99% in 2025.
• A 5-year view of Common Equity shows it stood at $303.7 million in 2022, then sank by 33.98% to $200.5 million in 2023, then jumped by 162.85% to $527.0 million in 2024, then advanced by 2.23% to $538.7 million in 2025, then dropped by 10.74% to $480.9 million in 2026.
• Business Quant data shows NRIX's Common Equity at $480.9 million in Q1 2026, $538.7 million in Q4 2025, and $372.3 million in Q3 2025.